Hypoxia-inducible factor-prolyl hydroxylase inhibitors in treatment of anemia with chronic disease.
10.1097/CM9.0000000000003470
- Author:
Zuolin LI
1
;
Lan SHEN
2
;
Yan TU
1
;
Shun LU
2
;
Bicheng LIU
1
Author Information
1. Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing, Jiangsu 210009, China.
2. Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
- Publication Type:Review
- Keywords:
Anemia of chronic disease;
Cancer;
Chronic kidney disease;
Hypoxia-inducible factor-prolyl hydroxylase inhibitors;
Iron metabolism
- MeSH:
Humans;
Anemia/metabolism*;
Chronic Disease;
Hypoxia-Inducible Factor-Proline Dioxygenases/metabolism*;
Erythropoietin/metabolism*;
Prolyl-Hydroxylase Inhibitors/therapeutic use*;
Animals;
Renal Insufficiency, Chronic
- From:
Chinese Medical Journal
2025;138(12):1424-1432
- CountryChina
- Language:English
-
Abstract:
Anemia of chronic disease (ACD) is the most frequent clinical issue in patients with chronic disease. ACD is usually secondary to chronic kidney disease (CKD), cancer, and chronic infection, which is associated with poor health outcomes, increased morbidity and mortality, and substantial economic costs. Current treatment options for ACD are very limited. The discovery of the hypoxia-inducible factor-prolyl hydroxylase (HIF-PHD) pathway made it possible to develop novel therapeutic agents (such as hypoxia-inducible factor-prolyl hydroxylase inhibitor, HIF-PHI) to treat ACD by stabilizing HIF and subsequently promoting endogenous erythropoietin (EPO) production and iron absorption and utilization. Thus, HIF-PHIs appear to open a new door for the treatment of ACD patients with a novel mechanism. Here, we comprehensively reviewed the latest advancements in the application of HIF-PHIs in ACD. Specifically, we highlighted the key features of HIF-PHIs on ACD, such as stimulation of endogenous EPO, handling iron metabolism, inflammation-independent, and prolonging lifespan of red blood cells. In conclusion, the success of HIF-PHIs in the treatment of ACD may expand the therapeutic opportunity for other types of anemia beyond renal anemia.
